15
Apr

Pfizer reported today that it had cut short a Phase III study of palbociclib, recently approved under an accelerated pathway as Ibrance, after clearly demonstrating that it had met its primary endpoint: progression-free survival with a combination of Ibrance plus fulvestrant in women with hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer.

…read more

Source: Pfizer’s palbociclib impresses in PhIII breast cancer study

    

0 No comments